Aisling Capital

Offices: New York (United States)

Investment Stages: Seed, Series A, Series B, Series C

Markets: Biopharma, Consumer, Diagnostics, Medical Device, Services

Founded Year: 2000

Investor Type: Venture Capital

Portfolio Companies: Aclaris Therapeutics, Inc., Adams Respiratory Therapeutics, Inc., ADMA Biologics, Inc., Advion, Inc., Aeglea BioTherapeutics, Inc., Agile Therapeutics, Inc., Aimmune Therapeutics, Inc., Ajax Health, Allos Therapeutics, Inc., Ambit Biosciences Corporation, Antios Therapeutics, Aragon Pharmaceuticals, Inc., Archimica Cooperatief U.A., Arcus Biosciences, Inc., ARMGO Pharma, Inc., ARMO BioSciences, Inc., Ascendis Pharma A/S, Aton Pharma, Inc., Atreca, Inc., Audentes Therapeutics, Inc., Auxilium Pharmaceuticals, Inc., AVANZA Laboratories, LLC, AVROBIO, Inc., Axcan Pharma, Inc., Barrier Therapeutics, Inc., Bicara Therapeutics, Bioenvision, Inc., Biohaven Pharmaceuticals Ltd., Biomea Fusion, Inc., BridgeBio Pharma LLC, CalciMedica, Inc., Cardiokine, Inc., Catalent, Inc., Cempra, Inc., Chimerix, Inc., Cidara Therapeutics, Inc., Clovis Oncology, Inc., CollaGenex Pharmaceuticals, Inc., Colorescience, Inc., COMPASS Pathways, Cynapsus Therapeutics Inc., Cytos Biotechnology AG, Dermira, Inc., Dren Bio, Durata Therapeutics, Inc., EarLens Corporation, Eidos Therapeutics, Elevation Oncology, Inc., Esperion Therapeutics, Inc., F2G Limited, Forge Biologics, Garuda Therapeutics, Inc., Global Blood Therapeutics, Inc., GTx, Inc., Harmony Biosciences, LLC, Ibrutinib Royalty, Infinity Pharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Intersect ENT, Inc., LENSAR, Inc., Lombard Medical, Inc., Loxo Oncology, Inc., MAP Pharmaceuticals, Inc., Marker Therapeutics, Inc., MKG LLC, MEI Pharma, Inc., Menlo Therapeutics Inc., Mindful Health Solutions, Miramar Labs, Inc., Monte Rosa Therapeutics, Inc., Myogen, Inc., Nabriva, NextWave Pharmaceuticals, Inc., Novazyme Pharmaceuticals, Inc., Nuvation Bio, Inc., ObsEva SA, Oculex Pharmaceuticals, Inc., Paratek Pharmaceuticals, Inc., PellePharm, Pernix Therapeutics, Inc., Pharmaron, Inc., Planet Biopharmaceuticals, Inc., Poseida Therapeutics, Inc., PowerVision, Inc., PreCision Dermatology, Inc., Prolacta Bioscience, Inc., Promentis Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Quintiles Transnational Holdings Inc., Reneo Pharmaceuticals, Inc., Roka Bioscience, Inc., Seragon Pharmaceuticals, Inc., Sirion Therapeutics, Inc., SkinMedica, Inc., Sorrento Therapeutics, Inc., Spirox, Inc., Spruce Biosciences, Spyre Therapeutics, Syndax Pharmaceuticals, Inc., Synergy Pharmaceuticals Inc., Syros Pharmaceuticals, Inc., T2 Biosystems, Inc., Talaris Therapeutics, Inc., Topaz Pharmaceuticals, Inc., TransEnterix, Inc., Treeline Biosciences, Inc., TRIA Beauty, Inc., Verona Pharma plc, Versartis, Inc., ViewRay, Inc., Viracta Pharmaceuticals, Inc., VIVUS, Inc., Wugen, Inc., Zavante Therapeutics, Inc., ZELTIQ Aesthetics, Inc., Zosano Pharma Corporation

Website: https://www.aislingcapital.com

Team Page: https://www.aislingcapital.com/team

Portfolio Link: https://www.aislingcapital.com/portfolio

LinkedIn: https://www.linkedin.com/company/aisling-capital

Twitter: https://twitter.com/AislingInvestor

Instagram:

Crunchbase: https://www.crunchbase.com/organization/aisling-capital

Pitchbook: https://pitchbook.com/profiles/investor/11270-71